Table 3.
Multivariate analysis of prognostic factors in 69 patients with NPC.
| Characteristic | OS | PFS | LRFS | DMFS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age (years)* | ||||||||||||
| <53 | NA | NA | NA | 0.25 | 0.09~0.72 | 0.01 | 0.10 | 0.01~0.92 | 0.04 | NA | NA | NA |
| ≥53 | Ref | Ref | Ref | Ref | ||||||||
| Clinical stage*a | ||||||||||||
| II | 0.00 | 0.00~5.95 | 0.96 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| III | 0.37 | 0.14~0.97 | 0.04 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| IVa | Ref | Ref | Ref | Ref | ||||||||
| T category*a | ||||||||||||
| T1-2 | NA | NA | NA | 0.11 | 0.02~0.86 | 0.04 | 0.00 | 0.00 | 0.98 | 0.13 | 0.02~1.02 | 0.05 |
| T3-4 | Ref | Ref | Ref | Ref | ||||||||
| N category*a | ||||||||||||
| N0-2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| N3 | Ref | Ref | Ref | Ref | ||||||||
| Therapy regimens* | ||||||||||||
| IMRT | Ref | Ref | Ref | Ref | ||||||||
| CCRT | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| ACCRT | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| MMR status* | ||||||||||||
| dMMR | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0.25 | 0.09~0.75 | 0.01 |
| pMMR | Ref | Ref | Ref | Ref | ||||||||
*Factors brought into the Cox proportional hazards regression model. aAccording to the AJCC TNM classification of malignant tumours 8th ed.
Abbreviations: Ref: reference group; NPC: nasopharyngeal carcinoma; MMR: mismatch repair; dMMR: deficient MMR; pMMR: proficient MMR; OS: overall survival; PFS: progression-free survival; DMFS: distant metastasis-free survival; LRFS: local recurrence-free survival; IMRT: intensity-modulated radiotherapy; CCRT: concurrent chemoradiotherapy; ACCRT: asynchronous combination chemoradiotherapy; HR: hazard ratio; NA: Not applicable.